Active Pharmaceutical Ingredient

Active Pharmaceutical Ingredient Market is Set to Grow to US$ 285.5 Billion by 2027

SHARE THIS ARTICLE

According to the report, the active pharmaceutical ingredient market size is projected to hit around US$ 285.5 billion by 2027, registering a CAGR of 6.82% from 2020 to 2027. The report provides the overall revenue of the global active pharmaceutical ingredient market from 2016 to 2027, considering 2020 as the base year and 2027 as the forecast year.

Active Pharmaceutical Ingredient (API) is the portion of drug that generates intentional effects. APIs are biologically and chemically active constituents of medicines with direct effect in mitigation, prevention, cure and treatment of diseases. Some of the medicines like combination therapies have many active ingredients to treat diverse symptoms or perform in numerous ways. Active Pharmaceutical Ingredient has active ingredient that is contained in medicine. For illustration, an active ingredient to reduce pain is incorporated in a painkiller. A slight amount of the active ingredient has result thus only small part of the active ingredient is confined in medicine.

Companies use certain principles to regulate strength of the API in all drugs. Nevertheless, these standards may vary extensively from one brand to other. Every brand may employ diverse test methods that may result in dissimilar potencies. Although many pharmaceutical firms are located in the U.S. and England, numerous API manufacturers are also located overseas. The biggest are situated in Asia Pacific, predominantly in India and China. Increasing numbers of organizations are outsourcing to curtail costs on employees, costly equipment, and infrastructure.

We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1035

Growth Factors

Continuously growing prevalence of chronic illness, escalating significance of generics, and the cumulative uptake of biopharmaceuticals are some of the prime factors stimulating the growth of the active pharmaceutical ingredient market globally. Alternatively, the critical drug price control policies in numerous nations and the swelling diffusion of counterfeit drugs may hamper the growth of API market in these nations during next few years. As per, 2017 NCBI article on a survey directed in a tertiary hospital in Japan, about 339 bacteremia UTI cases were identified. Thus, escalating occurrence of such infectious sickness and hospital-acquired contaminations are projected to stimulate growth of API market in the nearby future.

Some of the prime factors spurring the growth of the market are increasing occurrences of cardiovascular, oncology, lifestyle and diabetes diseases, intensifying number of diagnostic centers and hospitals and escalating elderly population in emerging countries. Furthermore, cumulative healthcare spending, growing disease responsiveness and education are propelling the growth of the market. Conversely, a shortage of accomplished workforce and inadequate accessibility of drugs in the emerging nations are hampering the growth of the market in these regions.

Report Highlights

  • Some of the tactical initiatives commenced by many business players to sustain stability in the market are biological products, new drugs launches, collaborations, acquisitions, and geographical expansion.
  • Oncology is projected to be the fastest-growing segment driven by developing pervasiveness of cancer and cumulative lifestyle-associated sicknesses.
  • In the event of outsourcing, APIs are subject to strict regulations and omission from the nation they are shipped to. For example, API manufacturing plants abroad still go via an scrutiny by the U.S. Food & Drug Administration.
  • API market has observed marvelous growth since last few decades due to augmented application of biologics and drugs in the treatment of diseases.

Regional Snapshots

In 2019, North America conquered the global market on account of high economic development plus widespread technological innovations in the region. Snowballing pervasiveness of cancer and other lifestyle-related illnesses inspires R&D undertakings by crucial market participants, thus enhancing the growth of the market. Asia Pacific is anticipated to record fastest growth in the market throughout the estimate period. On account of obtainability of affordable labor, foremost corporations in the market are setting up API business plants in emerging nations such as India and China.

Key Players & Strategies

Numerous companies are concentrating on widespread R&D for the development of drugs explicit to novel biomarkers. There are several APIs in the market for tumor treatment like Imatinib by Novartis and Trastuzumab, Bevacizumab, and Rituximab by Roche. Inorganic growth via acquisition and merger are some of the crucial tactics accepted by top business players since past few years. For example, Ranbaxy acquired Sun Pharmaceutical, to aid company appear as India’s uppermost drug manufacturer. Correspondingly, Hospira acquired API manufacturing facility and related R&D capacity of Orchid Chemicals & Pharmaceuticals Ltd. in July 2014.

Boehringer Ingelheim collaborated with Solve Care-an Estonian block-chain healthcare company to produce a Diabetes Care Administration Network In June 2019. The digital mode is intended at streamlining management tactics for patients with type 2 diabetes. This platform will allow patients to interconnect with healthcare suppliers, co-ordinate with specialists, comprehend their insurance, and access precise records.

Some of the noteworthy companies in the active pharmaceutical ingredient market include:

  • Albemarle Corporation
  • AurobindoPharma
  • Reddy’s Laboratories Ltd.
  • AbbVieInc
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V.
  • CiplaInc
  • BoehringerIngelheim International GmbH
  • Merck & Co., Inc
  • Sun Pharmaceutical Industries Ltd
  • Bristol-Myers Squibb Company

Segments Covered in the Report

This research report includes complete assessment of the market with the help of extensive qualitative and quantitative insights, and projections regarding the market. This report offers breakdown of market into prospective and niche sectors. Further, this research study calculates market revenue and its growth trend at global, regional, and country from 2016 to 2027. This report includes market segmentation and its revenue estimation by classifying it on the basis of Type of synthesis, type, application, type of manufacturer, and region as follows:

By Type of Manufacturer

  • Merchant APIs
  • Captive APIs

By Type

  • Generic APIs
  • Innovative APIs

By Type of Synthesis

  • Biotech
    • Recombinant Proteins
    • Monoclonal Antibodies
    • Vaccines
  • Synthetic

By Application

  • Orthopedic
  • Pulmonology
  • Gastroenterology
  • Endocrinology
  • Cardiology
  • Oncology
  • CNS & Neurology
  • Nephrology
  • Ophthalmology
  • Others

By Regional Outlook

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Middle East & Africa
  • Latin America

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global Active Pharmaceutical Ingredient Market, By Type of Manufacturer

7.1. Active Pharmaceutical Ingredient Market, by Type of Manufacturer Type, 2020-2027
7.1.1. Merchant APIs
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Captive APIs
7.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 8. Global Active Pharmaceutical Ingredient Market, By Type

8.1. Active Pharmaceutical Ingredient Market, by Type, 2020-2027
8.1.1. Generic APIs
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Innovative APIs
8.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Active Pharmaceutical Ingredient Market, By Type of Synthesis

9.1. Active Pharmaceutical Ingredient Market, by Type of Synthesis, 2020-2027
9.1.1. Biotech (Recombinant Proteins, Monoclonal Antibodies, Vaccines)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Synthetic
9.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global Active Pharmaceutical Ingredient Market, By Application

10.1. Active Pharmaceutical Ingredient Market, by Application, 2020-2027
10.1.1. Orthopedic
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Pulmonology
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Gastroenterology
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Endocrinology
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. Cardiology
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. Oncology
10.1.6.1. Market Revenue and Forecast (2016-2027)
10.1.7. CNS & Neurology
10.1.7.1. Market Revenue and Forecast (2016-2027)
10.1.8. Nephrology
10.1.8.1. Market Revenue and Forecast (2016-2027)
10.1.9. Other
10.1.9.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global Active Pharmaceutical Ingredient Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.1.2. Market Revenue and Forecast, by Type (2016-2027)
11.1.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.1.4. Market Revenue and Forecast, by Application (2016-2027)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.1.5.2. Market Revenue and Forecast, by Type (2016-2027)
11.1.5.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.1.5.4. Market Revenue and Forecast, by Application (2016-2027)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.1.6.2. Market Revenue and Forecast, by Type (2016-2027)
11.1.6.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.1.6.4. Market Revenue and Forecast, by Application (2016-2027)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.2.2. Market Revenue and Forecast, by Type (2016-2027)
11.2.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.2.4. Market Revenue and Forecast, by Application (2016-2027)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.2.5.2. Market Revenue and Forecast, by Type (2016-2027)
11.2.5.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.2.5.4. Market Revenue and Forecast, by Application (2016-2027)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.2.6.2. Market Revenue and Forecast, by Type (2016-2027)
11.2.6.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.2.6.4. Market Revenue and Forecast, by Application (2016-2027)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.2.7.2. Market Revenue and Forecast, by Type (2016-2027)
11.2.7.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.2.7.4. Market Revenue and Forecast, by Application (2016-2027)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.2.8.2. Market Revenue and Forecast, by Type (2016-2027)
11.2.8.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.2.8.4. Market Revenue and Forecast, by Application (2016-2027)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.3.2. Market Revenue and Forecast, by Type (2016-2027)
11.3.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.3.4. Market Revenue and Forecast, by Application (2016-2027)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.3.5.2. Market Revenue and Forecast, by Type (2016-2027)
11.3.5.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.3.5.4. Market Revenue and Forecast, by Application (2016-2027)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.3.6.2. Market Revenue and Forecast, by Type (2016-2027)
11.3.6.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.3.6.4. Market Revenue and Forecast, by Application (2016-2027)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.3.7.2. Market Revenue and Forecast, by Type (2016-2027)
11.3.7.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.3.7.4. Market Revenue and Forecast, by Application (2016-2027)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.3.8.2. Market Revenue and Forecast, by Type (2016-2027)
11.3.8.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.3.8.4. Market Revenue and Forecast, by Application (2016-2027)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.4.2. Market Revenue and Forecast, by Type (2016-2027)
11.4.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.4.4. Market Revenue and Forecast, by Application (2016-2027)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.4.5.2. Market Revenue and Forecast, by Type (2016-2027)
11.4.5.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.4.5.4. Market Revenue and Forecast, by Application (2016-2027)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.4.6.2. Market Revenue and Forecast, by Type (2016-2027)
11.4.6.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.4.6.4. Market Revenue and Forecast, by Application (2016-2027)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.4.7.2. Market Revenue and Forecast, by Type (2016-2027)
11.4.7.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.4.7.4. Market Revenue and Forecast, by Application (2016-2027)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.4.8.2. Market Revenue and Forecast, by Type (2016-2027)
11.4.8.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.4.8.4. Market Revenue and Forecast, by Application (2016-2027)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.5.2. Market Revenue and Forecast, by Type (2016-2027)
11.5.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.5.4. Market Revenue and Forecast, by Application (2016-2027)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.5.5.2. Market Revenue and Forecast, by Type (2016-2027)
11.5.5.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.5.5.4. Market Revenue and Forecast, by Application (2016-2027)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Type of Manufacturer (2016-2027)
11.5.6.2. Market Revenue and Forecast, by Type (2016-2027)
11.5.6.3. Market Revenue and Forecast, by Type of Synthesis (2016-2027)
11.5.6.4. Market Revenue and Forecast, by Application (2016-2027)

Chapter 12. Company Profiles

12.1. Albemarle Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AurobindoPharma
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Dr. Reddy’s Laboratories Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AbbVieInc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Teva Pharmaceutical Industries Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Mylan N.V.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. CiplaInc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. BoehringerIngelheim International GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck & Co., Inc
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sun Pharmaceutical Industries Ltd
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Bristol-Myers Squibb Company
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions

Chapter 14. Appendix

14.1. About Us
14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Why Buy this Report?

The purpose of Precedence Research’s active pharmaceutical ingredient market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1035

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. Email: sales@flairinsight.com

View all posts by Precedence Research →

Leave a Reply

Your email address will not be published. Required fields are marked *